Subtopic Deep Dive
Etoposide-Based Therapy for Hemophagocytic Lymphohistiocytosis
Research Guide
What is Etoposide-Based Therapy for Hemophagocytic Lymphohistiocytosis?
Etoposide-based therapy for hemophagocytic lymphohistiocytosis (HLH) uses etoposide in regimens like HLH-2004 to control hyperinflammation in primary and secondary HLH, bridging to hematopoietic stem cell transplantation.
HLH-2004 protocol combines etoposide, dexamethasone, and cyclosporine, showing confirmed efficacy in long-term outcomes (Bergsten et al., 2017, 620 citations). HLH-94 introduced chemoimmunotherapy with etoposide, improving survival from dismal prognosis (Trottestam et al., 2011, 658 citations). Etoposide remains central despite toxicity risks (Jordan et al., 2011, 1111 citations).
Why It Matters
Etoposide-based HLH-2004 therapy increased 5-year survival to 50% in primary HLH, enabling transplant (Bergsten et al., 2017). In secondary HLH, etoposide controls cytokine storm but requires toxicity management, as detailed in treatment guidelines (Jordan et al., 2011). Optimizing dosing reduces infections while maintaining efficacy, critical for pediatric patients (Trottestam et al., 2011). Real-world use spans infections, malignancies, and rheumatic triggers (George, 2014).
Key Research Challenges
Etoposide Toxicity Management
Etoposide causes myelosuppression and infections in HLH-2004, complicating therapy weeks 7-8 (Bergsten et al., 2017). Balancing dose reduction risks relapse (Trottestam et al., 2011). Long-term leukemia risk persists post-HLH (Jordan et al., 2011).
Primary vs Secondary HLH Efficacy
Etoposide works in both but outcomes differ; primary HLH needs faster transplant bridging (Bergsten et al., 2017). Secondary HLH triggered by infections varies response (George, 2014). Risk stratification improves protocols (Trottestam et al., 2011).
Salvage Therapy Optimization
Relapse after HLH-2004 requires etoposide re-induction or alternatives like emapalumab (Locatelli et al., 2020). Cytokine-directed therapies emerge for refractory cases (Schulert and Grom, 2014). Survival drops without rapid salvage (Jordan et al., 2011).
Essential Papers
How I treat hemophagocytic lymphohistiocytosis
Michael B. Jordan, Carl E. Allen, Sheila Weitzman et al. · 2011 · Blood · 1.1K citations
Abstract Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of pathologic immune activation, occurring as either a familial disorder or a sporadic condition, in association with a variety of tr...
Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol
Helena Trottestam, AnnaCarin Horne, Maurizio Aricò et al. · 2011 · Blood · 658 citations
Abstract Hemophagocytic lymphohistiocytosis (HLH) used to have a dismal prognosis. We report the final results of HLH-94, the largest prospective diagnostic/therapeutic HLH study so far. The treatm...
Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study
Elisabet Bergsten, AnnaCarin Horne, Maurizio Aricò et al. · 2017 · Blood · 620 citations
Key Points Early introduction of cyclosporine did not improve HLH outcome in patients treated with the HLH-94 etoposide-dexamethasone backbone (P = .06). HLH-2004 may be improved by risk-group stra...
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
Franco Locatelli, Michael B. Jordan, Carl E. Allen et al. · 2020 · New England Journal of Medicine · 471 citations
Emapalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis. (Funded by NovImmune and the European Commission; NI-0501-04 and NI-0501-05 ClinicalTria...
Hemophagocytic lymphohistiocytosis: review of etiologies and management
Melissa R. George · 2014 · Journal of Blood Medicine · 468 citations
Hemophagocytic lymphohistiocytosis (HLH) covers a wide array of related life-threatening conditions featuring ineffective immunity characterized by an uncontrolled hyperinflammatory response. HLH i...
Immunopathogenesis and treatment of cytokine storm in COVID-19
Jae‐Seok Kim, Jun Young Lee, Jae Won Yang et al. · 2020 · Theranostics · 459 citations
Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine storm refers to a set of clinic...
Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies
Grant S. Schulert, Alexei A. Grom · 2014 · Annual Review of Medicine · 393 citations
Macrophage activation syndrome (MAS) is an acute episode of overwhelming inflammation characterized by activation and expansion of T lymphocytes and hemophagocytic macrophages. In rheumatology, it ...
Reading Guide
Foundational Papers
Start with Jordan et al. (2011, 1111 citations) for clinical treatment overview; follow with Trottestam et al. (2011, 658 citations) for HLH-94 etoposide results; add George (2014, 468 citations) for etiologies.
Recent Advances
Bergsten et al. (2017, 620 citations) details HLH-2004 long-term data; Locatelli et al. (2020, 471 citations) contrasts emapalumab alternatives.
Core Methods
Etoposide-dexamethasone pulses in 8-week induction; cyclosporine for T-cell control; response monitored by ferritin, cytopenias (HLH-2004 per Bergsten et al., 2017).
How PapersFlow Helps You Research Etoposide-Based Therapy for Hemophagocytic Lymphohistiocytosis
Discover & Search
Research Agent uses searchPapers for 'etoposide HLH-2004 outcomes' yielding Bergsten et al. (2017), then citationGraph reveals HLH-94 roots (Trottestam et al., 2011) and findSimilarPapers uncovers toxicity studies; exaSearch drills into 250M+ OpenAlex for unpublished protocols.
Analyze & Verify
Analysis Agent applies readPaperContent to extract HLH-2004 survival stats from Bergsten et al. (2017), verifies response with CoVe against Jordan et al. (2011) guidelines, and runPythonAnalysis computes meta-analysis of 620+ cited outcomes using GRADE for evidence strength in etoposide dosing.
Synthesize & Write
Synthesis Agent detects gaps in toxicity data between HLH-94 and HLH-2004 via contradiction flagging, then Writing Agent uses latexEditText for protocol comparisons, latexSyncCitations for 10+ papers, latexCompile for figures, and exportMermaid for treatment flowcharts.
Use Cases
"Extract survival curves from HLH-2004 etoposide data and plot Kaplan-Meier."
Research Agent → searchPapers('HLH-2004 etoposide') → Analysis Agent → readPaperContent(Bergsten 2017) → runPythonAnalysis(pandas/matplotlib sandbox plots GRADE-verified curves).
"Draft LaTeX review comparing HLH-94 vs HLH-2004 etoposide efficacy."
Synthesis Agent → gap detection(Trottestam 2011, Bergsten 2017) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile(PDF with toxicity table).
"Find code for HLH cytokine storm simulations linked to etoposide models."
Research Agent → searchPapers('HLH cytokine model etoposide') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(pulls Python sims for Jordan 2011 cytokine data).
Automated Workflows
Deep Research workflow scans 50+ HLH papers via searchPapers → citationGraph → DeepScan 7-steps with CoVe checkpoints on etoposide outcomes (Bergsten 2017). Theorizer generates dosing hypotheses from HLH-94/2004 data contrasts (Trottestam 2011). DeepScan verifies toxicity stats across Jordan 2011 reviews.
Frequently Asked Questions
What defines etoposide-based therapy in HLH?
Etoposide (150 mg/m² IV twice weekly) anchors HLH-2004 with dexamethasone and cyclosporine for 8 weeks, per Bergsten et al. (2017).
What are key methods in etoposide HLH protocols?
HLH-94 used 8-week etoposide induction; HLH-2004 added early cyclosporine but saw no outcome gain (Trottestam et al., 2011; Bergsten et al., 2017).
What are seminal papers on etoposide HLH therapy?
Jordan et al. (2011, 1111 citations) provides 'How I treat HLH'; Trottestam et al. (2011, 658 citations) reports HLH-94 results; Bergsten et al. (2017, 620 citations) confirms HLH-2004 efficacy.
What open problems exist in etoposide HLH research?
Toxicity-driven dose reductions risk relapse; salvage for refractory cases needs optimization; primary/secondary HLH response differences require stratification (Bergsten et al., 2017; Jordan et al., 2011).
Research Autoimmune and Inflammatory Disorders Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Etoposide-Based Therapy for Hemophagocytic Lymphohistiocytosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers